BBT-176 / Bridge Biotherap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  BBT-176 / Bridge Biotherap
    Trial completion date, Trial termination, Metastases:  Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov) -  Dec 5, 2023   
    P1/2,  N=45, Terminated, 
    No abstract available Trial completion date: Jun 2024 --> Nov 2023 | Active, not recruiting --> Terminated; Sponsor's decision considering the changing treatment landscape for NSCLC
  • ||||||||||  BBT-176 / Bridge Biotherap
    Enrollment closed, Enrollment change, Metastases:  Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (clinicaltrials.gov) -  Oct 18, 2023   
    P1/2,  N=45, Active, not recruiting, 
    Trial completion date: Jun 2024 --> Nov 2023 | Active, not recruiting --> Terminated; Sponsor's decision considering the changing treatment landscape for NSCLC Recruiting --> Active, not recruiting | N=168 --> 45
  • ||||||||||  BBT-401 / Bridge Biotherap, Daewoong Pharma, BBT-176 / Bridge Biotherap, BBT-877 / Bridge Biotherap
    Bridge Biotherapeutics, Inc (Theater 3) -  Jun 4, 2022 - Abstract #BIO2022BIO_408;    
    is a publicly traded clinical-stage biotech company based in the Republic of Korea with labs and offices in the U.S. Founded in 2015, Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics for disease indications with high unmet medical needs including cancer, ulcerative colitis, and fibrotic diseases. The company's clinical pipeline includes BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis; BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF); and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.
  • ||||||||||  BBT-176 / Bridge Biotherap
    Identification of next-generation EGFR degraders to treat non-small cell lung cancer (NSCLC) patients (Section 26) -  Mar 9, 2022 - Abstract #AACR2022AACR_2699;    
    A PK study of C-4383 in rats showed good exposure with moderate CL when administered intravenously (CL = 8.51 mL/min/kg, AUC = 5911 ng•h/mL).In summary, we identified heterobifunctional degraders using a 4th generation EGFR inhibitor, BBT-176, that are active in EGFR mutant NSCLC cells harboring single or C797S-containing multiple mutations. We are currently making our efforts on the improvement of physicochemical properties of EGFR mutant targeted heterobifunctional compounds.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy () -  Jul 22, 2021 - Abstract #ESMO2021ESMO_2649;    
    P1/2
    Background: First- and third-generation epidermal growth factor receptor (EGFR) inhibitors such as gefitinib and osimertinib, respectively, have improved survival outcomes for patients with advanced EGFR-mutant NSCLC...Synergistic efficacy of BBT-176 with Cetuximab was also observed in animal studies...When RP2D is determined in Part 1, then Part 2 will be initiated to evaluate efficacy in molecularly selected target populations. Objective response rate, duration of response and progression-free survival will be measured in addition to safety and tolerability of BBT-176 at RP2D (NCT04820023).